Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $3.50.

Several brokerages have recently weighed in on NKTR. BTIG Research restated a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a report on Monday, September 30th. Piper Sandler initiated coverage on Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target on the stock.

Nektar Therapeutics Stock Up 4.0 %

Shares of NKTR opened at $1.05 on Monday. Nektar Therapeutics has a 52-week low of $0.42 and a 52-week high of $1.93. The firm has a market capitalization of $193.68 million, a PE ratio of -1.25 and a beta of 0.61. The firm has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.31.

Hedge Funds Weigh In On Nektar Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new stake in Nektar Therapeutics in the 2nd quarter valued at $29,000. Valence8 US LP bought a new stake in shares of Nektar Therapeutics during the third quarter worth $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics during the 3rd quarter worth approximately $41,000. XTX Topco Ltd bought a new stake in shares of Nektar Therapeutics during the 3rd quarter valued at $46,000. Finally, Values First Advisors Inc. bought a new stake in Nektar Therapeutics in the second quarter valued at about $56,000. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.